Carisma Therapeutics INC. (CARM) — 10-Q Filings

All 10-Q filings from Carisma Therapeutics INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Carisma Swings to Profit Amid Wind-Down, Nasdaq Delisting — Nov 12, 2025 Risk: high
Carisma Therapeutics Inc. (CARM) reported a significant turnaround in the nine months ended September 30, 2025, achieving a net income of $25.677 million, a sub
Carisma Merges with OrthoCellix, Pivots to Gene Therapy — Aug 7, 2025 Risk: high
Carisma Therapeutics Inc. (CARM) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's n
Carisma Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
Carisma Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Sesen Bio, Inc., is involved in pharmaceutical pre
Carisma Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
Carisma Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Sesen Bio, Inc., is involved in pharmaceutical
Carisma Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
Carisma Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op
Carisma Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk:
Carisma Therapeutics Inc. (CARM) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Carisma Therapeutics Inc. filed a 10-Q report for the quarterly pe

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX